1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,833 | 0,865 | 04.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Cereno Scientific Announces Sten R. Sörensen Named Finalist for 'CEO of the Year' at the European Lifestars Awards 2025 | 1 | Cision News | ||
| Di | Cereno Scientific Participates at GoCo Investor Day on September 9, 2025, in Gothenburg | 1 | Cision News | ||
| 27.08. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2025 (April 1 - June 30, 2025) | 626 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 26.08. | Cereno Scientific AB: Cereno Scientific Granted FDA Fast Track Designation for CS1 in Rare Disease Pulmonary Arterial Hypertension (PAH) | 342 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 06.08. | Cereno Scientific announces conversion of convertibles following request by Fenja Capital II A/S and Arena Investors, LP | 2 | Cision News | ||
| 17.07. | Cereno Scientific - Phase II calling for CS014 after Phase I success | 335 | Edison Investment Research | Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic pulmonary fibrosis (IPF). The candidate demonstrated favourable... ► Artikel lesen | |
| 15.07. | Cereno Scientific AB: Cereno Scientific announces positive topline results from Phase I trial of CS014 - a novel HDAC inhibitor - supporting advancement into Phase II | 120 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive... ► Artikel lesen | |
| 30.06. | Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July | 4 | Cision News | ||
| 23.06. | Cereno Scientific - Improved liquidity with latest debt financing | 335 | Edison Investment Research | Cereno Scientific has bolstered its liquidity position through a SEK25m loan facility secured from new Danish investors Venusat and SAJ Finans. Concurrently, the company executed an addendum to its... ► Artikel lesen | |
| 20.06. | Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II | 1 | Cision News | ||
| 17.06. | Cereno Scientific - Four-month EAP data support CS1 plans | 330 | Edison Investment Research | Cereno Scientific has announced encouraging four-month follow-up data from its Expanded Access Program (EAP) for CS1, a first-in-class HDAC inhibitor being developed to treat pulmonary arterial hypertension... ► Artikel lesen | |
| 16.06. | Cereno Scientific AB: Cereno Scientific shares 4-month follow-up data from Expanded Access Program in line with Phase IIa trial results of CS1 in rare disease PAH | 217 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced 4-month... ► Artikel lesen | |
| 10.06. | Cereno Scientific AB: Cereno Scientific shares the report from Annual General Meeting 2025 | 199 | GlobeNewswire (Europe) | Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the... ► Artikel lesen | |
| 27.05. | Cereno Scientific - Firing on all cylinders | 459 | Edison Investment Research | In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement... ► Artikel lesen | |
| 27.05. | Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 2025 | 1 | Cision News | ||
| 23.05. | Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | 183 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 22.05. | Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025) | 318 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 15.05. | Cereno Scientific publishes Annual Report for 2024 | 1 | Cision News | ||
| 13.05. | Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | 2 | Cision News | ||
| 09.05. | Cereno Scientific give notice to attend the Annual General Meeting 2025 | 1 | Cision News |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,215 | +0,11 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| EVOTEC | 5,702 | -2,70 % | Insiderkäufe und Datenpanne - Evotec, naoo AG, PayPal | In der deutschen Wirtschaft herrscht zunehmend Unruhe und nicht jeder Vorstand sitzt mehr sicher im Sattel. Der Volkswagen Konzern ist ins Straucheln geraten und die Frage, ob der Vorstandschef Oliver... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 33,175 | 0,00 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| BIONTECH | 89,10 | +3,42 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| SUMMIT THERAPEUTICS | 23,805 | 0,00 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| RECURSION PHARMACEUTICALS | 4,515 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| CG ONCOLOGY | 30,900 | 0,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| BOLT PROJECTS | 4,300 | 0,00 % | Bolt Projects Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 16,905 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,680 | 0,00 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| TAYSHA GENE THERAPIES | 3,260 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
| BEAM THERAPEUTICS | 18,560 | -1,07 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 19,760 | -0,05 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,000 | +0,84 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| NOVAVAX | 6,685 | +5,38 % | Novavax gets Japan nod for its COVID-19 vaccine, triggers Takeda payment |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,866 Euro und damit +0,93 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.